ClinicalTrials.gg
Not yet recruitingNCT06931301Updated Jul 1, 2026

Effect of HBOT on Femoral Head Avascular Necrosis (AVN)

An interventional study of Hyperbaric Oxygen Therapy in Osteonecrosis and Avascular Necrosis, sponsored by Yale University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Yale University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to determine whether the Hyperbaric Oxygen Therapy (HBOT) conducted under the Marx Protocol improves pain outcomes when combined with core decompression with autologous bone marrow aspirate concentrate to treat patients with femoral head avascular necrosis.

02

Conditions studied

  • Osteonecrosis
  • Avascular Necrosis

Browse trials for

03

In context

Osteonecrosis

286 studies on the registry are indexed under Osteonecrosis; 45 are open to participants now.

This study's planned enrollment of 400 is above the median of 68 across 151 interventional studies indexed under Osteonecrosis.

Browse Osteonecrosis studies →

Lead sponsor

Yale University is the lead sponsor of 1,770 studies on the registry; 294 are open to participants now.

Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Diagnosed with femoral head avascular necrosis
  • Enrolled into Yale Avascular Necrosis Program
  • Avascular necrosis lesion is classified as ARCO I or ARCO II by Investigator
  • Surgical Candidate for Core Decompression using 3D image guidance with bone marrow aspirate concentrate

Exclusion criteria

Exclusion Criteria:

  • Hip has already collapsed due to severe avascular necrosis (ARCO III or ARCO IV)
  • Medical comorbidities that prevent them from being a surgical candidate (example: obesity)
  • Absolute to HBOT, including severe decompensated cardiac failure or lung disease putting them at high risk for pneumothorax
  • Pregnant
  • Prisoner
  • Does not sign Form
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Hyperbaric Oxygen Therapy- Full Marx Protocol

    30 treatments before surgery, and 10 treatments after surgery

    Device: Hyperbaric Oxygen Therapy

  • Experimental
    Hyperbaric Oxygen Therapy- Reduced Marx Protocol

    20 treatments before surgery and 10 treatments after surgery

    Device: Hyperbaric Oxygen Therapy

  • No intervention
    Control

    No hyperbaric oxygen therapy

  • Experimental
    HBOT outside Yale

    The participant is having HBOT sessions at a different location (outside of the Yale New Haven Health system). These treatments will be overseen by the outside facility's HBOT Director and completed according to the Marx protocol . The patient is responsible for picking a site, setting up their intake appointments, and going to the treatments. The patient is also responsible for providing the HBOT site Director with our protocol as well as returning a completed form that indicates that the proper protocol was used.

    Device: Hyperbaric Oxygen Therapy

Interventions

  • DeviceHyperbaric Oxygen Therapy

    Sechrist Monoplace Hyperbaric Chamber Model 3600, Chamber will be used to supply patients with 100% oxygen to breathe at 2-2.4 ATA (the equivalent of diving to 33 - 45 feet of sea water) for two hours, 5 treatments per week

06

What researchers measure

Primary outcomes

  1. Change in Pain scores measured with the Visual Analog Scale (VAS).

    Participants will be asked to mark a point on a 100 mm horizontal line that represents the intensity of their pain. This line has two endpoints: 0: No pain and 10: Worst possible pain imaginable. The distance from the "0" to the mark is measured in millimeters with the resulting number (0-10) being the VAS pain score.

    Time frame: baseline, after every 5 treatments of HBOT treatment, 6 weeks, 4.5 months, 9 months, 1 year, 2 years, 3 years, 4 years, and 5 years

Secondary outcomes

  1. Change in Pain interference PROMIS questionnaire scores

    The PROMIS Pain Interference measures the self-reported consequences of pain on a person's life. Total score range 40 to 80 with higher scores indicating worse outcomes.

    Time frame: baseline, after every 5 treatments of HBOT treatment, 6 weeks, 4.5 months, 9 months, 1 year, 2 years, 3 years, 4 years, and 5 years

  2. Change in Physical function/mobility PROMIS questionnaire scores

    PROMIS Physical Function measures self-reported capability of physical activities. Scores range from 80-20. A lower T-score represents a worse physical function.

    Time frame: baseline, after every 5 treatments of HBOT treatment, 6 weeks, 4.5 months, 9 months, 1 year, 2 years, 3 years, 4 years, and 5 years

  3. Change in Oxford Hip Scores (OHS)

    OHS is an assessment of 12 items of patient-reported outcomes to assess pain and function after hip replacement surgery. Total score range 0 to 48 with higher scores indicating better outcomes.

    Time frame: baseline, after every 5 treatments of HBOT treatment, 6 weeks, 4.5 months, 9 months, 1 year, 2 years, 3 years, 4 years, and 5 years

  4. Change in ARCO classification

    Number of Participants that had a change in ARCO 2019 classification using x-rays of hip to determine classification.

    Time frame: baseline, 6 weeks, 4.5 months, 9 months, 1 year, 2 years, 3 years, 4 years, and 5 years

07

Study locations

1 site
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06931301
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Apr 17, 2025
Start date
Dec 2026 (estimated)
Primary completion
Apr 2035 (estimated)
Completion
Apr 2035 (estimated)
Last update
Jul 1, 2026

Study contacts

Daniel Wiznia
Contact
daniel.wiznia@yale.edu
203-785-2579
Rummana Aslam, MD
principal investigator · Yale University

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion